Osteogenesis imperfecta: Questions and answers

Current Opinion in Pediatrics

Volumn 21, Issue 6, 2009, Pages 709-716

  Shapiro, Jay R ^a   Sponsellor, Paul D ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Bisphosphonate; Collagen; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DNA; NARCOTIC AGENT; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BONE BIOPSY; BONE TURNOVER; BRACE; CLINICAL TRIAL; COL1A1 GENE; COL1A2 GENE; CRTAP GENE; DNA DETERMINATION; FRACTURE; FRACTURE HEALING; GENE; GENE MUTATION; HUMAN; INTRAMEDULLARY NAILING; LEPRE1 GENE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAIN; PATHOGENESIS; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; RECESSIVE INHERITANCE; REVIEW; SCOLIOSIS; SKIN BIOPSY; TOOTH MALFORMATION; TREATMENT DURATION; TREATMENT INDICATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; BRACES; CHILD; DIPHOSPHONATES; HUMANS; INTERNAL FIXATORS; OSTEOGENESIS IMPERFECTA; SCOLIOSIS;

EID: 74549185663     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328332c68f     Document Type: Review

References (43)

1. Pace JM, Wiese M, Drenguis AS, et al. Defective C-propeptides of the proalpha2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta. J Biol Chem 2008; 283:16061-16067.
2. KörkköJ, Annunen S, Pihlajamaa T, et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A 1998; 95:1681-1685.
3. Bodian DL, Chan TF, Poon A, et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum Mol Genet 2009; 18:463-471.
4. Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006; 127:291-304.
5. Pepin M, Atkinson M, Starman BJ, Byers PH. Strategies and outcomes of prenatal diagnosis for osteogenesis imperfecta: a review of biochemical and molecular studies completed in 129 pregnancies. Prenat Diagn 1997; 17:559-570.
6. Hsieh CT, Yeh GP, Wu HH, et al. Fetus with osteogenesis imperfecta presenting as increased nuchal translucency thickness in the first trimester. J Clin Ultrasound 2008; 36:119-122.
7. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16:101-116.
8. Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007; 28:209-221.
9. Bodian DL, Madhan B, Brodsky B, Klein TE. Predicting the clinical lethality of osteogenesis imperfecta from collagen glycine mutations. Biochemistry 2008; 47:5424-5432.
10. Wallis GA, Sykes B, Byers PH, et al. Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. J Med Genet 1993; 30:492-496.
11. Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31:12-18. (Pubitemid 34754419)
12. Labuda M, Morissette J, Ward LM, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31:19-25.
13. Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 2006; 355:2757-2764.
14. Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007; 39:359-365.
15. Willaert A, Malfait F, Symoens S, et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet 2009; 46:233-241.
16. Baldridge D, Schwarze U, Morello R, et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 2008; 29:1435-1442.
17. Obafemi AA, Bulas DI, Troendle J, Marini JC. Popcorn calcification in osteogenesis imperfecta: incidence, progression, and molecular correlation. Am J Med Genet A 2008; 146:2725-2732.
18. Ha-Vinh R, Alanay Y, Bank RA, et al. Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2. Am J Med Genet A 2004; 131:115-120.
19. Andiran N, Alikasifoglu A, Alanay Y, Yordam N. Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment. Pediatr Int 2008; 50:836-838.
20. Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 2009; 22: 55-63.
21. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxy-terminal propeptide in type I procollagen. J Bone Mineral Res 2003; 18:237-243.
22. Martin EN, Khosravi A, BrintzenhofeSoc K, et al. Vitamin D deficiency in osteogenesis imperfecta. Am J Bone Min Res 2007; 22 (Suppl 1):S341.
23. Antoniazzi F, Zamboni G, Lauriola S, et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006; 149:174-179.
24. Aström E, Jorulf H, Söderhäll S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 2007; 92:332-338.
25. Munns CF, Rauch F, Travers R, et al. Effects of intravenous pamidronate in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Min Res 2005; 20:1235-1243.
26. Bachrach LK, Ward LM. Clinical review. 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009; 94:400-409.
27. Rauch F, Travers R, Glorieux F. Pamidronate treatment with osteogenesis imperfecta: histomorphometric effects of long term therapy. J Clin Endocrinol 2006; 92:511-515.
28. Rauch F, Cornibert S, Cheung M, et al. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007; 40:821-827.
29. Glorieux FH. Treatment of osteogenesis imperfecta: who, why, what? Horm Res 2007; 68 (Suppl 5):8-11.
30. Hackley L, Merritt L. Osteogenesis imperfecta in the neonate. Adv Neonat Care 2008; 8:21-30.
31. Aström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86:356-364.
32. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20:977-986.
33. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008; 4: CD005088.
34. Castillo H, Samson-Fang L, American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009; 51:17-29.
35. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21:132-410.
36. Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr 2008; 45:105-109.
37. Rauch F, Munns C, Land C, et al. Residronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Mineral Res 2009; 24:1282-1289.
38. Bishop N, Harrison R, Ahmed F, et al. A randomized controlled dose-ranging study of residronate in children with moderate and severe osteogenesis imperfecta. J Bone Min Res 2009. [Epub ahead of print]
39. Zeitlin L, Fassier F, Glorieux F. Modern approach to osteogenesis imperfecta. J Pediatr Orthop B 2003; 12:77-87.
40. Sponseller PD, Mesfin A. Spine deformity secondary to dysplasias and other diseases. In: Kim DH, Betz RR, Huhn SL, Newton PO, editors. Surgery of the pediatric spine. New York: Thieme Medical Publisher; 2007.
41. Song D, Maher CO. Spinal disorders associated with skeletal dysplasias and syndromes. Neurosurg Clin N Am 2007; 18:499-514.
42. Widmann RF, Bitan FD, Laplaza FJ, et al. Spinal deformity, pulmonary compromise, andqualityoflifeinosteogenesisimperfecta.Spine1999;24:1673-1678.
43. JanusGJ, Finidori G, Engelbert RH, et al.Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J 2000; 9:486-491.